Premium
A double‐blind, randomized, placebo‐controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis
Author(s) -
Hancke Juan L.,
Srivastav Shalini,
Cáceres Dante D.,
Burgos Rafael A.
Publication year - 2019
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.6339
Subject(s) - osteoarthritis , womac , medicine , placebo , andrographis paniculata , andrographolide , physical therapy , knee pain , quality of life (healthcare) , placebo controlled study , randomized controlled trial , arthritis , double blind , pharmacology , alternative medicine , nursing , pathology
Andrographis paniculata Wall (Acanthaceae) is becoming more recognized for its anti‐inflammatory and antioxidant properties. A randomized, double‐blind, placebo‐controlled study was conducted to assess the efficacy of an andrographolide‐containing supplement, ParActin® (300 and 600 mg daily), on Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain reduction in patients with knee osteoarthritis. Joint stiffness, physical function, changes in the SF‐36 quality of life questionnaire, a fatigue scale, and safety were also evaluated. A total of 103 male and female patients with I‐II osteoarthritis of the knee joint were assessed. Patients treated with 300 or 600 mg/day of ParActin® showed a significant reduction in pain at days 28, 56, and 84 compared with a placebo group. WOMAC stiffness scores, physical function score, and the fatigue score showed a significant improvement in both ParActin®‐treated groups compared with the placebo group. At the end of the study, the quality of life (SF‐36 questionnaire) and Functional Assessment of Chronic Illness Therapy (FACIT) scores showed significant improvements in both ParActin®‐treated groups compared with the placebo group. Overall, it can be concluded that ParActin® in 300 and 600 mg/day dosages were found to be effective and safe in reducing pain in individuals suffering from mild to moderate knee osteoarthritis.